1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AptarGroup reported fourth-quarter 2024 net income of $101 million, up 62%, with reported sales up 1% to $848 million and core sales up 2%. The company guided first-quarter 2025 adjusted EPS to $1.11 to $1.19, below the $1.19 adjusted EPS it reported for the first quarter of 2024, citing an expected currency headwind of about 7 cents and a higher tax rate.
Q4 2024 diluted EPS was $1.49 vs $0.93 a year earlier; adjusted EPS was $1.52, up 27%
Q4 reported sales rose 1% to $848 million; core sales rose 2%, with currency a negative effect
Q1 2025 adjusted EPS guidance of $1.11 to $1.19 vs $1.19 adjusted in Q1 2024; FX headwind of about 7 cents
Board approved a $0.45 quarterly dividend payable February 26, 2025 and a $500 million share repurchase authorization
Minerals Technologies reported fourth-quarter and full-year 2024 results in a press release furnished under Item 2.02 of a Form 8-K dated February 6, 2025. Fourth-quarter net sales slipped 1% to $518.1 million while diluted EPS rose to $1.68 from $1.22, and full-year net sales fell 2% to $2.12 billion while diluted EPS more than doubled to $5.17 from $2.58. The filing does not include forward guidance, and the company will discuss the results on a conference call on February 7, 2025.
Q4 2024 net sales were $518.1 million, down 1% from $524.5 million in Q4 2023.
Q4 diluted EPS was $1.68 versus $1.22; excluding special items, it was $1.50 versus $1.28.
Full-year 2024 net sales were $2.12 billion, down 2%; diluted EPS was $5.17 versus $2.58, or $6.15 versus $5.21 excluding special items.
In 2024 the company repurchased $64 million of shares and repaid $39 million of debt.
Globus Medical agreed to acquire Nevro Corp. in an all-cash transaction valued at approximately $250 million in total equity value, subject to Nevro shareholder approval, regulatory clearance and other closing conditions. Globus Medical said that after the deal closes it expects higher 2025 net sales but lower non-GAAP earnings per share than its stand-alone guidance.
Nevro shareholders will receive $5.85 per share in cash, a 17% premium to Nevro's February 5, 2025 closing price.
Globus Medical expects the deal to close late in the second quarter of 2025 and anticipates the Nevro acquisition to be accretive to earnings in the second year of operation.
Post-deal 2025 guidance: net sales of $2.80 billion to $2.90 billion (versus stand-alone $2.66 billion to $2.69 billion) and non-GAAP EPS of $3.10 to $3.40 (versus stand-alone $3.40 to $3.50).
Termination fees: Nevro would pay $15 million or $10 million in certain circumstances, including a failed stockholder vote; Globus Medical would pay $15 million in certain circumstances.
On February 4, 2025, Sprinklr committed to a reduction in force affecting about 15% of its global workforce as of January 31, 2025, which it says will realign employee costs with the current business and free up capital for investments in go-to-market and R&D resources. The company estimates about $25 million in non-recurring charges, mostly in the first and second quarters of fiscal 2026. It also expects its results for the quarter and fiscal year ended January 31, 2025 to be in line with or above its December 4, 2024 guidance, with formal guidance to come at its March 2025 earnings call.
Reduction in force of about 15% of global workforce, committed February 4, 2025
Estimated non-recurring charges of about $25 million, mostly in Q1 and Q2 of fiscal 2026
Preliminary quarter and fiscal year ended January 31, 2025 results expected in line with or above December 4, 2024 guidance
Formal guidance for quarter ending April 30, 2025 and fiscal 2026 to be provided at March 2025 earnings call
Cousins Properties reported fourth-quarter 2024 results on February 6, 2025. Funds from operations (FFO) rose to $108.9 million, or $0.69 per share, from $98.3 million, or $0.65 per share, a year earlier, while net income available to common stockholders fell to $13.6 million, or $0.09 per share, from $18.8 million, or $0.12 per share, which the company attributed mainly to higher depreciation. The company also gave initial 2025 guidance of FFO between $2.73 and $2.83 per share.
Q4 2024 FFO was $108.9 million, or $0.69 per share, versus $98.3 million, or $0.65 per share, in Q4 2023.
Q4 2024 net income available to common stockholders was $13.6 million, or $0.09 per share, versus $18.8 million, or $0.12 per share.
Full-year 2024 FFO was $414.1 million, or $2.69 per share, versus $398.3 million, or $2.62 per share, in 2023.
2025 guidance: net income of $0.25 to $0.35 per share and FFO of $2.73 to $2.83 per share.
Mohawk Industries reported fourth-quarter 2024 net sales of $2.6 billion, up 1.0% as reported but down 1.0% on an adjusted basis, and diluted EPS of $1.48 versus $2.18 a year earlier. Adjusted EPS was $1.95 versus $1.96, and the company expects first-quarter 2025 adjusted EPS of $1.34 to $1.44, including a $0.35 impact from order management system problems in its Flooring North America segment.
Q4 2024 net earnings were $93 million, or $1.48 per diluted share, compared with $140 million, or $2.18, in Q4 2023; adjusted diluted EPS was $1.95 versus $1.96.
Full-year 2024 diluted EPS was $8.14 versus a loss of $6.90 in 2023, which included $878 million of impairment charges; full-year adjusted EPS of $9.70 rose about 6%.
First-quarter 2025 adjusted EPS is expected between $1.34 and $1.44, with the company citing ongoing softness in all markets and a $0.35 EPS impact from system issues.
Free cash flow for 2024 was $680 million and the company repurchased 1.3 million shares for $161 million.
EastGroup Properties reported fourth-quarter 2024 diluted EPS of $1.16, down from $1.35 a year earlier, mainly because the 2023 quarter included $13 million in property sale gains and there were no sales in the 2024 quarter. Funds from operations (FFO) excluding gains on involuntary conversion and business interruption claims rose 5.9% to $2.15 per diluted share, and the company set 2025 guidance of $8.80 to $9.00 in FFO per share.
Q4 2024 diluted EPS was $1.16 versus $1.35 in Q4 2023; the 2023 quarter included $13 million in real estate sale gains and there were no sales in Q4 2024.
Q4 2024 FFO excluding certain claim gains was $2.15 per diluted share versus $2.03, an increase of 5.9%.
Full-year 2024 diluted EPS was $4.66 versus $4.42, and FFO excluding certain claim gains was $8.31 versus $7.70, an increase of 7.9%.
2025 guidance calls for EPS of $4.71 to $4.91 and FFO of $8.80 to $9.00 per diluted share.
Genpact reported full-year 2024 net revenues of $4.77 billion, up 6.5%, and adjusted diluted EPS of $3.28, up 10%. GAAP diluted EPS fell 16% to $2.85 and net income fell 19% to $514 million, with the 2023 comparison including a $170 million non-recurring tax benefit. The company also raised its quarterly dividend 11% to $0.17 and added $500 million to its share repurchase authorization, and it guided to 2025 adjusted diluted EPS of $3.52 to $3.59.
Full-year 2024 net revenues were $4.77 billion, up 6.5%; fourth-quarter net revenues were $1.25 billion, up 8.9%
Diluted EPS was $2.85, down 16%; adjusted diluted EPS was $3.28, up 10%
2025 outlook: net revenues of $5.029 billion to $5.125 billion and adjusted diluted EPS of $3.52 to $3.59
Quarterly dividend raised to $0.17 per share (11% increase), payable March 26, 2025; repurchase authorization increased by $500 million
For the fiscal third quarter ended December 31, 2024, Take-Two reported net bookings of $1.37 billion, up 3% from $1.34 billion a year earlier, while GAAP net revenue was $1.36 billion, down from $1.37 billion. The GAAP net loss widened to $125.2 million, or $0.71 per share, from $91.6 million, or $0.54 per share, and the company reiterated its fiscal 2025 net bookings guidance of $5.55 billion to $5.65 billion. Shareholders are weighing bookings growth against a larger loss and slightly lower revenue.
Net bookings were $1.37 billion, up 3% from $1.34 billion; recurrent consumer spending grew 9%.
GAAP net revenue was $1.36 billion, compared with $1.37 billion in the prior-year quarter.
GAAP net loss was $125.2 million, or $0.71 per share, versus $91.6 million, or $0.54 per share, a year earlier.
Fiscal 2025 net bookings guidance was reiterated at $5.55 billion to $5.65 billion; fiscal fourth-quarter net bookings outlook is $1.484 billion to $1.584 billion.
VeriSign reported fourth-quarter 2024 revenue of $395 million, up 3.9%, but net income fell to $191 million from $265 million, and diluted EPS fell to $2.00 from $2.60. The prior-year quarter included a $69.3 million income tax benefit. For full-year 2024, revenue rose 4.3% to $1.56 billion and diluted EPS rose to $8.00 from $7.90, while net income declined to $786 million from $818 million.
Q4 2024 revenue $395 million, up 3.9% from Q4 2023; Q4 operating income $264 million vs. $256 million
Q4 2024 net income $191 million and diluted EPS $2.00, vs. $265 million and $2.60 in Q4 2023, which included a $69.3 million tax benefit
Full-year 2024 revenue $1.56 billion, up 4.3%; diluted EPS $8.00 vs. $7.90; net income $786 million vs. $818 million
Full-year 2024 share repurchases totaled $1.21 billion; $1.02 billion remained under the program as of Dec. 31, 2024
Power Integrations reported fourth-quarter 2024 revenue of $105.2 million, up 18% from a year earlier but down 9% from the prior quarter, with GAAP diluted EPS of $0.16 versus $0.25 a year earlier. For full-year 2024, revenue fell to $419.0 million from $444.5 million and GAAP diluted EPS fell to $0.56 from $0.97. The company guided first-quarter 2025 revenue to be flat with the fourth quarter, plus or minus five percent.
Q4 2024 net revenues were $105.2 million, up 18% year over year and down 9% from Q3 2024.
Q4 2024 GAAP diluted EPS was $0.16 and non-GAAP diluted EPS was $0.30, versus $0.25 and $0.22 a year earlier.
Full-year 2024 net revenues were $419.0 million versus $444.5 million in 2023; GAAP diluted EPS was $0.56 versus $0.97.
Q1 2025 outlook: revenue flat versus Q4 2024 plus or minus 5%; GAAP gross margin 55% to 55.5%.
For the quarter ended December 31, 2024, e.l.f. Beauty reported net sales up 31% to $355.3 million, but GAAP diluted earnings per share fell to $0.30 from $0.46 a year earlier. The company lowered its fiscal 2025 outlook, with net sales now expected at $1,300-1,310 million versus the prior $1,315-1,335 million, and it cited softer than expected trends in January.
Q3 net sales rose 31% to $355.3 million; GAAP net income was $17.3 million versus $26.9 million a year earlier.
Q3 GAAP diluted EPS was $0.30 versus $0.46; adjusted diluted EPS was $0.74, flat with the prior year.
Fiscal 2025 net sales outlook cut to $1,300-1,310 million from $1,315-1,335 million; adjusted EBITDA outlook cut to $289-293 million from $304-308 million.
CFO Mandy Fields said the company is taking a prudent approach to the final fiscal quarter given softer January trends.
Paylocity reported second-quarter fiscal 2025 results for the three months ended December 31, 2024, with total revenue of $377.0 million, up 16% from a year earlier. GAAP net income was $37.5 million, or $0.66 per diluted share, down from $38.1 million, or $0.67, a year earlier, and the company said it increased its revenue and profitability guidance for fiscal 2025.
Total revenue was $377.0 million, up 16%; recurring and other revenue was $347.7 million, up 17%.
GAAP net income was $37.5 million, or $0.66 per diluted share, versus $38.1 million, or $0.67, a year earlier.
Fiscal 2025 total revenue is now expected at $1.558 billion to $1.568 billion; adjusted EBITDA at $542.0 million to $550.0 million.
Long-term debt of $325.0 million reflects borrowings to fund the Airbase acquisition on October 1, 2024.
Qualys reported fourth-quarter 2024 revenue of $159.2 million, up 10% year over year, with GAAP net income of $44.0 million and GAAP diluted EPS of $1.19 versus $1.08 a year earlier. The company also guided 2025 revenue to $645.0 million to $657.0 million (6% to 8% growth) and non-GAAP diluted EPS to $5.50 to $5.90, below the $6.13 reported for 2024, and said it would increase its share repurchase program by $200 million.
Q4 2024 non-GAAP net income was $59.4 million, or $1.60 per diluted share, versus $1.40 a year earlier.
Full-year 2024 revenue was $607.6 million, up 10%, and GAAP net income was $173.7 million, or $4.65 per diluted share.
2025 guidance: full-year GAAP EPS of $3.62 to $4.02 and non-GAAP EPS of $5.50 to $5.90; Q1 2025 revenue of $155.5 million to $158.5 million.
Share repurchase program increased by $200 million; 2024 repurchases of common stock totaled $139.9 million.
StepStone reported results for the quarter ended December 31, 2024, with total revenues of $339.0 million, compared with negative $14.6 million a year earlier. The GAAP net loss attributable to StepStone widened to $192.0 million, or $2.61 per diluted share, as equity-based compensation rose to $486.4 million, while non-GAAP measures such as fee-related earnings and adjusted net income grew, and the board declared a $0.24 quarterly dividend.
GAAP net loss attributable to StepStone was $192.0 million, or $2.61 per diluted share, versus a loss of $20.2 million, or $0.32 per share, a year earlier.
Equity-based compensation was $486.4 million, compared with $14.0 million in the prior-year quarter.
Adjusted revenues were $243.9 million, up 32%; fee-related earnings were $74.1 million, up 46%; ANI per share was $0.44 versus $0.37.
Board declared a $0.24 per share quarterly dividend, payable March 14, 2025, to holders of record on February 28, 2025.
Neurocrine Biosciences reported fourth-quarter 2024 total revenues of $627.7 million, up from $515.2 million a year earlier, driven by INGREZZA net product sales of $615 million. GAAP net income fell to $103.1 million, or $1.00 per diluted share, from $147.7 million, or $1.44, as operating expenses rose, while non-GAAP diluted EPS rose to $1.69 from $1.54. The company also issued full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.6 billion.
Q4 2024 total revenues $627.7 million vs. $515.2 million in Q4 2023; full-year 2024 total revenues $2,355.3 million vs. $1,887.1 million
Q4 2024 GAAP diluted EPS $1.00 vs. $1.44; non-GAAP diluted EPS $1.69 vs. $1.54, with the company citing $28 million of higher stock-based compensation tied to CRENESSITY approval and the CEO retirement charge
CRENESSITY fourth-quarter 2024 net product sales were $2 million, reflecting initial pharmacy orders after FDA approval in December 2024
Full-year 2025 guidance: INGREZZA net product sales of $2.5 billion to $2.6 billion; non-GAAP R&D of $890 million to $940 million and non-GAAP SG&A of $955 million to $975 million
AGCO reported fourth-quarter and full-year 2024 results on February 6, 2025. Full-year net sales fell 19.1% to $11.7 billion, and reported net loss was $(5.69) per share, compared with net income of $15.63 per share in 2023, after impairment charges, restructuring costs and a $507.3 million loss on the sale of the Grain & Protein business. The company reaffirmed its 2025 outlook of net sales of about $9.6 billion and earnings per share of $4.00 to $4.50, which shareholders will watch as industry demand weakens.
Full-year 2024 adjusted net income was $7.50 per share, versus $15.55 in 2023 (non-GAAP).
Fourth-quarter 2024 net sales were $2.9 billion, down 24.0%, with a reported net loss of $(3.42) per share.
2025 outlook: net sales of about $9.6 billion, adjusted operating margin of about 7% to 7.5%, and earnings per share of $4.00 to $4.50.
Darling Ingredients reported fourth-quarter 2024 net income of $101.9 million, or $0.63 per diluted share, up from $0.52 a year earlier, while net sales fell to $1.4 billion from $1.6 billion and Combined Adjusted EBITDA fell to $289.5 million from $350.9 million. For fiscal 2024, net income fell to $278.9 million from $647.7 million, and the company gave 2025 Combined Adjusted EBITDA guidance of $1.25 to $1.30 billion, compared with $1.08 billion in 2024.
Q4 2024 net income attributable to Darling was $101.9 million, or $0.63 per diluted share, versus $84.5 million, or $0.52, in Q4 2023.
Q4 2024 total net sales were $1.4 billion, down from $1.6 billion, reflecting lower finished product pricing.
Fiscal 2024 net income was $278.9 million, or $1.73 per diluted share, versus $647.7 million, or $3.99, in fiscal 2023.
2025 guidance calls for Combined Adjusted EBITDA of $1.25 to $1.30 billion, versus $1.08 billion for fiscal 2024.
Patrick Industries reported fourth-quarter 2024 net sales up 8% to $846 million, helped by acquisitions and higher Housing revenue, but operating income fell 31% to $40 million and diluted EPS dropped to $0.42 from $0.94. For full year 2024, net sales rose 7% to $3.7 billion while diluted EPS fell to $4.11 from $4.33. The board also declared a $0.40 quarterly dividend per share.
Q4 2024 net sales $846 million, up 8%; operating income $40 million, down 31%
Q4 2024 diluted EPS $0.42 versus $0.94 a year earlier; adjusted diluted EPS $0.52
Full year 2024 net sales $3.7 billion, up 7%; diluted EPS $4.11 versus $4.33 in 2023
Quarterly dividend of $0.40 per share, payable March 3, 2025, to holders of record on February 18, 2025
BorgWarner reported fourth quarter 2024 net sales of $3,439 million, down 2.4%, and a GAAP net loss of $(1.84) per diluted share, driven by $646 million of goodwill and fixed asset impairment charges. The company also gave 2025 guidance for net sales of $13.4 billion to $14.0 billion and GAAP earnings of $3.84 to $4.12 per diluted share, and declared a quarterly dividend of $0.11 per share.
Q4 2024 GAAP net loss of $(1.84) per diluted share, compared with earnings of $0.64 in Q4 2023; adjusted EPS was $1.01 versus $0.90
Full-year 2024 net sales of $14,086 million, down 0.8%; GAAP EPS $1.63 versus $2.70 in 2023
2025 guidance: net sales $13.4 billion to $14.0 billion, adjusted EPS $4.05 to $4.40, free cash flow $650 million to $750 million
Quarterly dividend of $0.11 per share, payable March 17, 2025, to holders of record on March 3, 2025
Insight Enterprises reported fourth-quarter 2024 net sales of $2.1 billion, down 7% year over year, and net earnings of $37.0 million, down 59%. For the full year, net sales fell 5% to $8.7 billion, while Adjusted diluted earnings per share were flat at $9.68 and gross margin reached a record 20.3%. The company expects 2025 Adjusted diluted earnings per share of $9.70 to $10.10.
Q4 2024 net sales were $2.1 billion, down 7%, while gross profit rose 1% to $439.6 million
Q4 2024 net earnings were $37.0 million and diluted earnings per share were $0.99, versus $2.42 a year earlier
Full year 2024 net sales were $8.7 billion, down 5%, and Adjusted diluted earnings per share were $9.68, flat year over year
2025 outlook: Adjusted diluted earnings per share of $9.70 to $10.10, with gross margin expected to remain approximately 20%
Belden reported fourth-quarter 2024 revenue of $666 million, up 21% year over year, and GAAP EPS of $1.42, up from $0.91. For the full year, revenue fell 2% to $2,461 million and GAAP EPS fell to $4.80 from $5.66. The company guided first-quarter 2025 revenue to $605 million to $620 million and adjusted EPS to $1.43 to $1.53.
Q4 2024 revenue of $666 million, up 21% year over year and up 14% organically
Full-year 2024 revenue of $2,461 million, down 2%; GAAP EPS of $4.80 versus $5.66 a year earlier
Full-year 2024 adjusted EPS of $6.36, down 7% from $6.83
Q1 2025 guidance: revenue $605 million to $620 million; adjusted EPS $1.43 to $1.53
Under Armour reported third-quarter fiscal 2025 revenue down 6% to $1.4 billion, with net income of $1 million compared with $111 million a year earlier. The company raised its adjusted diluted EPS outlook to $0.28 to $0.30 from $0.24 to $0.27, while still expecting revenue to fall about 10% for the year, which matters to shareholders because results and guidance point in different directions.
Q3 revenue fell 6% to $1.4 billion; North America fell 8% to $844 million.
Q3 GAAP net income was $1 million; adjusted net income was $35 million; adjusted diluted EPS was $0.08.
Fiscal 2025 adjusted diluted EPS outlook raised to $0.28 to $0.30 from $0.24 to $0.27; GAAP diluted loss per share expected at $0.48 to $0.50.
Restructuring plan range increased to $140 million to $160 million; company had $727 million in cash at quarter end.
Maximus reported fiscal first-quarter 2025 revenue of $1.40 billion, up 5.7% from a year earlier, and raised its full-year fiscal 2025 adjusted diluted EPS guidance to $5.90 to $6.20. GAAP diluted EPS fell to $0.69 from $1.04 because of about $38 million in divestiture-related charges, which shareholders will weigh against the higher adjusted results and guidance.
Revenue rose 5.7% to $1.40 billion; U.S. Federal Services revenue rose 15.3% to $780.7 million.
Diluted EPS was $0.69 versus $1.04 a year earlier; adjusted diluted EPS was $1.61 versus $1.34.
Full-year fiscal 2025 revenue guidance is $5.2 billion to $5.35 billion, and free cash flow guidance is $355 million to $385 million.
Q1 cash used in operating activities was $80.0 million; the company bought back 3.1 million shares for $237 million in the quarter.
Advanced Drainage Systems (ADS) reported unaudited results for the fiscal third quarter ended December 31, 2024, with net sales rising 4.3% while net income and diluted EPS fell. The company confirmed its previously issued fiscal 2025 targets of $2.900 billion to $2.975 billion in net sales and $880 million to $920 million in Adjusted EBITDA, and declared a $0.16 per share cash dividend, which matters to shareholders because profit fell even as sales grew.
Net sales rose $28.2 million, or 4.3%, to $690.5 million; net income fell 23.0% to $82.3 million
Diluted EPS was $1.04, down from $1.34; Adjusted EBITDA fell 6.2% to $191.5 million
Fiscal 2025 guidance was confirmed: net sales $2.900 billion to $2.975 billion, Adjusted EBITDA $880 million to $920 million
Cash dividend of $0.16 per share is payable March 14, 2025, to holders of record on February 28, 2025
MACOM reported fiscal first quarter 2025 revenue of $218.1 million, up 38.8% from a year earlier and 8.7% from the prior quarter. A $193.1 million loss on debt extinguishment tied to a refinancing of its 0.25% convertible senior notes due 2026 produced a GAAP net loss of $167.5 million, or $2.30 per diluted share. The company also guided fiscal second quarter revenue to $227 million to $233 million and adjusted diluted EPS to $0.82 to $0.86.
Revenue $218.1 million, up 38.8% year over year from $157.1 million and up 8.7% from $200.7 million in the prior quarter
GAAP net loss of $167.5 million, or $2.30 per diluted share, including a $193.1 million loss on debt extinguishment, versus net income of $29.4 million in the prior quarter
Adjusted net income of $59.5 million, or $0.79 per diluted share, compared with $0.58 a year earlier
Fiscal second quarter outlook (quarter ending April 4, 2025): revenue of $227 million to $233 million and adjusted EPS of $0.82 to $0.86
Lear reported fourth-quarter 2024 sales of $5.7 billion, down from $5.8 billion a year earlier, and net income of $88 million, down from $127 million. For full-year 2024, net income fell to $507 million from $573 million and GAAP earnings per share fell to $8.97 from $9.68, while adjusted earnings per share rose 5% to $12.62. The company also issued a 2025 outlook with net sales of $21,875 million to $22,875 million.
Q4 2024 net income $88 million vs $127 million in Q4 2023; EPS $1.61 vs $2.18
Full-year 2024 net income $507 million vs $573 million; adjusted EPS $12.62 vs $12.02
2025 outlook: net sales $21,875 million to $22,875 million; core operating earnings $915 million to $1,175 million
Repurchased $400 million of shares and paid $174 million in dividends in 2024
Peloton reported fiscal Q2 2025 results for the quarter ended December 31, 2024, with total revenue of $673.9 million, down 9% year over year but $13.9 million above the high end of its $640 million to $660 million guidance range. The company raised its full-year fiscal 2025 Adjusted EBITDA guidance to $300 million to $350 million from $240 million to $290 million and its Free Cash Flow target to at least $200 million from $125 million.
Q2 total revenue was $673.9 million, down 9% year over year, and above the $640 million to $660 million guidance range.
Net loss was $92.0 million, an improvement of $102.9 million year over year; Adjusted EBITDA was $58.4 million.
Free Cash Flow was $106.0 million in Q2, and cash and cash equivalents ended the quarter at $829.0 million.
FY25 Adjusted EBITDA guidance was raised to $300 million to $350 million from $240 million to $290 million; Free Cash Flow target was raised to at least $200 million from $125 million.
Affiliated Managers Group reported fourth-quarter 2024 revenue of $524.2 million, up from $502.7 million a year earlier, while diluted EPS fell to $4.92 from $5.15 and controlling-interest net income fell to $162.1 million from $196.2 million. For full-year 2024, economic EPS rose 10% to $21.36 while GAAP diluted EPS fell to $15.13 from $17.42, and the company repurchased $700 million of stock.
Q4 2024 revenue was $524.2 million vs. $502.7 million in Q4 2023; Q4 diluted EPS was $4.92 vs. $5.15
Q4 economic EPS was $6.53 vs. $6.86; full-year 2024 economic EPS was $21.36 vs. $19.48
Full-year 2024 revenue was $2,040.9 million vs. $2,057.8 million; 2023 GAAP results included Affiliate Transaction gains of $133.1 million
Board declared a $0.01 per share quarterly dividend, payable March 4, 2025 to holders of record on February 18, 2025
Aptiv reported fourth quarter 2024 revenue of $4.9 billion, flat year over year, and U.S. GAAP earnings of $1.14 per diluted share, down from $3.22 a year earlier. The prior-year quarter included a $680 million tax benefit, while adjusted earnings rose to $1.75 per share from $1.40. The company also guided 2025 U.S. GAAP diluted EPS to $5.25 to $5.85, below 2024's $6.96, and adjusted EPS to $7.00 to $7.60, above 2024's $6.26.
Q4 2024 U.S. GAAP diluted EPS was $1.14 versus $3.22 in Q4 2023; adjusted EPS was $1.75 versus $1.40.
Full-year 2024 revenue was $19.7 billion, down 2%, and U.S. GAAP diluted EPS was $6.96.
2025 guidance: U.S. GAAP diluted EPS of $5.25 to $5.85 and adjusted EPS of $7.00 to $7.60, excluding potential impacts of recent U.S. tariffs.
Aptiv repurchased shares for about $3.35 billion in 2024 and plans to complete its accelerated share repurchase by Q2 2025.
Regal Rexnord reported fourth-quarter 2024 results with net sales of $1,461.1 million, down 9.1% from the prior year, and adjusted diluted EPS of $2.34, up 2.6%. The company also introduced 2025 guidance for adjusted diluted EPS of $9.60 to $10.40, which shareholders will use to compare future performance.
Q4 2024 GAAP diluted EPS was $0.62, versus $0.84 in the prior-year quarter
Q4 net sales were $1,461.1 million, down 9.1% year over year and down 1.4% on an organic basis
2025 guidance: GAAP diluted EPS of $4.42 to $5.22 and adjusted diluted EPS of $9.60 to $10.40
Company paid down $205 million of gross debt in the fourth quarter
XPO reported fourth-quarter and full-year 2024 results. Q4 revenue fell 1.0% to $1.92 billion, mainly on lower fuel surcharge revenue in North American LTL, while diluted EPS from continuing operations rose to $0.63 from $0.49. Full-year diluted EPS more than doubled to $3.23 from $1.62, and full-year revenue rose 4.2% to $8.07 billion, so shareholders see higher profit on softer quarterly sales.
Q4 2024 revenue was $1.92 billion, versus $1.94 billion in Q4 2023.
Q4 2024 adjusted diluted EPS was $0.89, versus $0.77; a $34 million real estate gain added $0.21 per diluted share.
Full-year 2024 adjusted diluted EPS was $3.83, versus $2.92 in 2023.
North American LTL Q4 adjusted operating income was $159 million, flat versus $160 million a year earlier.
Omnicell reported fourth-quarter 2024 revenue of $307 million, up 19% from a year earlier, and GAAP net income of $16 million, compared with a loss of $14 million in the prior-year quarter. For the full year, revenue fell 3% to $1.112 billion and non-GAAP earnings per diluted share fell to $1.71 from $1.91, so shareholders see a mixed picture. The company also gave 2025 guidance for total revenue of $1.105 billion to $1.155 billion and non-GAAP earnings per share of $1.65 to $1.85.
Q4 2024 total revenue was $307 million, up $48 million, or 19%, from Q4 2023; full-year revenue was $1.112 billion, down $35 million, or 3%.
Full-year 2024 GAAP net income was $13 million, or $0.27 per diluted share, versus a GAAP net loss of $20 million in 2023.
Full-year 2024 non-GAAP net income was $79 million, or $1.71 per diluted share, versus $87 million, or $1.91, in 2023; non-GAAP EBITDA was $136 million versus $138 million.
2025 guidance: total revenue of $1.105 billion to $1.155 billion and non-GAAP EBITDA of $140 million to $155 million.
nVent reported fourth-quarter 2024 sales of $752 million, up 9% but down 1% organically, and a GAAP loss of $0.10 per diluted share from continuing operations, compared with EPS of $1.26 a year earlier. Adjusted EPS rose 7% to $0.59, while the GAAP loss reflected a $92.8 million tax valuation allowance recorded in the quarter. The company also issued 2025 guidance of 8% to 10% reported sales growth and GAAP EPS of $2.45 to $2.55.
Q4 2024 sales $752 million, up 9%; organic sales down 1%
Q4 GAAP EPS from continuing operations $(0.10) vs. $1.26 a year earlier; adjusted EPS $0.59, up 7%; tax valuation allowance of $92.8 million
Full-year 2024 sales $3.0 billion, up 13%; GAAP EPS $1.43, down 48%; adjusted EPS $2.49, up 7%
2025 guidance: reported sales up 8% to 10%; GAAP EPS $2.45 to $2.55; adjusted EPS $2.98 to $3.08
MarketAxess reported fourth-quarter 2024 revenue of $202.4 million, up 3% from a year earlier, while net income fell 6% to $65.1 million and diluted EPS fell 6% to $1.73. For the full year, revenue rose 9% to $817.1 million and diluted EPS rose 6% to $7.28, and the company guided 2025 expenses to $505.0 million to $525.0 million. The board also declared a quarterly dividend of $0.76 per share.
Q4 2024 total revenue of $202.4 million, up 3%; net income of $65.1 million, down 6%
Full year 2024 total revenue of $817.1 million, up 9%; diluted EPS of $7.28, up 6%
Quarterly cash dividend of $0.76 per share, payable March 5, 2025 to holders of record on February 19, 2025
2025 expense guidance of $505.0 million to $525.0 million; midpoint implies an increase of approximately 8%
Haemonetics reported third-quarter fiscal 2025 revenue of $348.5 million, up 3.7%, and GAAP earnings of $0.74 per diluted share, up from $0.61. The company lowered its fiscal 2025 reported revenue growth guidance to 3% to 5% from 5% to 8% and cut free cash flow guidance to $120 million to $140 million from $130 million to $180 million, while narrowing its adjusted earnings per share guidance to $4.50 to $4.70.
Third-quarter revenue was $348.5 million, up 3.7%, while organic revenue decreased 0.3%.
GAAP earnings per diluted share were $0.74, versus $0.61 a year earlier; adjusted earnings per diluted share were $1.19, up 14.4%.
Fiscal 2025 reported revenue growth guidance was lowered to 3% to 5% from 5% to 8%.
Free cash flow guidance was cut to $120 million to $140 million from $130 million to $180 million; adjusted earnings per share guidance was narrowed to $4.50 to $4.70 from $4.45 to $4.75.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.